Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.…
How Investors May Respond To Alpha Tau Medical Stock After Glioblastoma Trial Results
Alpha Tau Medical (NASDAQ: DRTS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 121 employees.
The shares were at 11.76 USD on 20 November 2026, up 198.4% over 52 weeks. Its 52-week range is 3.430 USD to 15.63 USD: the price is 24.8% below the high and 242.7% above the low.
Its market capitalisation is 1.09B USD.
Alpha Tau Medical reports return on equity of -55.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 85.49M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 20.60 USD is 75.2% above the current price. The next earnings report is expected on 8 March 2027.